Fulcrum Therapeutics Announces $175 Million Public Offering

Fulcrum Therapeutics ( (FULC) ) has shared an announcement.

On December 10, 2025, Fulcrum Therapeutics announced the pricing of its underwritten public offering, which includes 11,851,853 shares of common stock and pre-funded warrants to purchase up to 1,111,193 shares, raising gross proceeds of $175 million. The offering is expected to close on December 11, 2025, and the net proceeds will be used for general corporate purposes, including working capital, research and development, and potential acquisitions, positioning Fulcrum to enhance its operations and market presence.

The most recent analyst rating on (FULC) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.

Spark’s Take on FULC Stock

According to Spark, TipRanks’ AI Analyst, FULC is a Neutral.

Fulcrum Therapeutics’ overall stock score is driven by strong technical momentum and promising clinical trial results, despite challenges in profitability and valuation concerns. The company’s robust financial position and strategic growth plans provide a solid foundation for future advancements.

To see Spark’s full report on FULC stock, click here.

More about Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Average Trading Volume: 1,173,075

Technical Sentiment Signal: Buy

Current Market Cap: $790.1M

See more data about FULC stock on TipRanks’ Stock Analysis page.